Latest news

CARB-X Funds The 3rd Round of Debiopharm’s Targeted Antibiotic Program To Combat Resistant N. Gonorrhoeae Infections

Debiopharm & Dexa Medica Launch Triptorelin Collaboration to Bring New Hope To Women With Endometriosis

Debiopharm Encourages Breakthough Cancer Research In Japan Through its Competitive JCA Mauvernay Award

6e Challenge Qualité de vie du patient : cinq finalistes reçoivent 5000 francs chacun et avancent en finale

Debiopharm and Ubix Therapeutics launch research to develop a new anti-cancer modality – antibody degraducer® conjugates

Debiopharm’s CD37 antibody drug conjugate shows promising phase II results for the treatment of B-cell malignancies

Debiopharm Collaborates With Innocentive For The Launch of A Global Challenge To Develop A Single-Dose mRNA Covid-19 Vaccine

Debiopharm Launches the “IDEAL” Initiative to Strengthen the Lemanic Region as a Hub for Life Science Innvovation

Debiopharm Grants a Worldwide Exclusive License to Merck for the Development and Commercialization of Xevinapant